Phage Therapy Breaks New Ground in Combating Drug-Resistant Mycobacterial Infections

In the ongoing battle against drug-resistant Mycobacterial infections, a ray of hope has emerged from the world of bacteriophages. The study, titled "Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease," which was published in the Oxford Academic Journal explores an innovative approach to tackling the growing challenges posed by Mycobacterium infections, particularly Mycobacterium abscessus. These infections are on the rise, especially among individuals with cystic fibrosis and chronic bronchiectatic lung diseases, creating a pressing need for effective treatment options.

The study delves into the promising field of phage therapy, offering new insights into the personalized identification of lytic phages for Mycobacterium isolates and their compassionate use in 20 patients. This article highlights the study's key findings, emphasizing its potential to revolutionize the management of drug-resistant Mycobacterial infections.

The Mycobacterial Challenge

Nontuberculous Mycobacterium infections, particularly Mycobacterium abscessus, have become increasingly prevalent and problematic among patients with underlying lung conditions. The inherent antibiotic resistance of these pathogens has made treatment a formidable challenge, leading researchers to explore alternative therapeutic avenues.

Phage Therapy: A Glimmer of Hope

Bacteriophage therapy, or phage therapy for short, offers a promising and novel approach to combating drug-resistant Mycobacterial infections. Phages, which are viruses that target and infect bacteria, can be harnessed to specifically attack Mycobacterium species. However, the study reveals that there are relatively few active lytic phages available for this purpose, and susceptibility to phages varies significantly among different M. abscessus isolates. Therefore, a personalized approach to phage identification becomes essential.

Scheme for identifying therapeutically suitable mycobacteriophages
A method for identifying mycobacteriophages that are appropriate for therapeutic use To ascertain colony morphotype and homogeneity clinical isolates on slants top are grown in liquid and streaked on solid media Both smooth and rough colony morphotypes are purified then cultivated and checked The efficiency of plaquing EOP on the bacterial isolate in comparison to Mycobacterium smegmatis control was assessed using a panel of phages once the slant looked to be homogeneous each strain was assigned a GDxx identifier In order to determine the effectiveness of killing and the chance of phage resistance arising phages that were infected with an EOP > 01 were subsequently evaluated in a killing experiment over a range of bacterial phage concentrations and in a survival assay The approximate screening timeline is displayed on the left

Compassionate Use of Phages: A Lifeline for Desperate Patients

The study, conducted on 20 patients as part of compassionate use, administered phages intravenously, by aerosolization, or both, and closely monitored their responses. Notably, the results were exceptionally promising:

  1. Safety First: No adverse reactions were observed in any of the patients, irrespective of the pathogen, type of phages administered, or route of delivery. This underscores the safety profile of phage therapy as a viable treatment option.
  2. Clinical and Microbiological Responses: Encouragingly, 11 out of the 20 patients demonstrated favorable clinical or microbiological responses to phage therapy. This suggests that phages could play a pivotal role in managing drug-resistant Mycobacterial infections when traditional antibiotics fall short.
  3. Resistance: A Minimal Concern: Intriguingly, none of the 11 patients treated with a single phage exhibited any signs of phage resistance. This is a remarkable finding, highlighting the potential durability of this treatment strategy.
  4. Neutralizing Antibodies: While neutralizing antibodies were identified in serum after initiating intravenous phage delivery in eight patients, they were not consistently associated with unfavorable responses. This nuanced aspect of the study opens avenues for further exploration into optimizing phage therapy.

A New Frontier in Mycobacterial Infection Treatment

This study continues to illuminate the potential of phage therapy as a lifeline for patients battling drug-resistant Mycobacterial infections. Despite the challenges posed by limited therapeutic phages and variable susceptibilities, the favorable outcomes in patients with no other treatment options underscore the need for continued development of adjunctive phage therapy.

Phage therapy, with its impeccable safety record and encouraging clinical and microbiological responses, has the potential to redefine the landscape of Mycobacterial infection treatment. As researchers delve deeper into phage discovery and optimization, we may be on the cusp of a medical breakthrough that offers renewed hope for patients facing this formidable healthcare challenge. The study's findings serve as a beacon, guiding the way toward a brighter future in the fight against drug-resistant Mycobacterial infections.

You can read the full article here Dedrick, R. M., Smith, B. E., Cristinziano, M., Freeman, K. G., Jacobs-Sera, D., Belessis, Y., ... & Hatfull, G. F. (2023). Phage therapy of Mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial diseaseClinical infectious diseases76(1), 103-112.

About the author

Hello there!
I'm Raphael Hans Lwesya, My true passion lies in the world of phage research and science communication. As a diligent phage researcher and an enthusiastic science communicator, I've founded "," a platform dedicated to unraveling the fascinating universe of bacteriophages – viruses that specifically target microbes. My ultimate mission is to bridge the communication gap between the general public and the often intricate world of scientific concepts. I take pride in simplifying complex ideas, breaking them down into easily understandable pieces, and making cutting-edge phage-related research accessible to a wide audience. Thank you for visiting The Phage blog. If you have got any question or suggestion please drop it as a comment or via [email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *